-transparent.png){kind=logo}
To compare proteinuric potentials among angiotensin II (ANG II) and its fragments, [des-Asp1]-angiotensin II (ANG III) and [des-Asp1, des-Arg2]-angiotensin II (ANG IV), the peptide was intravenously infused for 30 min at doses of 0.015, 0.05, 0.15, 0.45 and 1.45 nmol/kg body weight/min. The infusion of ANG II and ANG III increased the fractional clearance of albumin in a dose-dependent manner: most extensively for ANG II, and moderately for ANG III. In contrast, the infusion of ANG IV hardly showed any proteinuric action, even at the maximal dose of 1.45 nmol/kg body weight/min. These results denoted that the cleaving of the N-terminal aspartic acid1 from ANG II weakened the proteinuric action in the glomeruli, and the further cleaving of the N-terminal arginine from ANG III led to a complete loss of proteinuric action in the glomeruli.
J Terui, and
K Tamoto, and
J Sudo
April 1982,
Acta endocrinologica,
J Terui, and
K Tamoto, and
J Sudo
December 1975,
Endocrinologia japonica,
J Terui, and
K Tamoto, and
J Sudo
January 1983,
Life sciences,
J Terui, and
K Tamoto, and
J Sudo
January 1982,
Clinical and experimental pharmacology & physiology. Supplement,
J Terui, and
K Tamoto, and
J Sudo
March 1979,
The American journal of physiology,
J Terui, and
K Tamoto, and
J Sudo
December 1975,
Journal of medicinal chemistry,
J Terui, and
K Tamoto, and
J Sudo
September 1977,
Endocrinology,
J Terui, and
K Tamoto, and
J Sudo
April 1977,
Federation proceedings,
J Terui, and
K Tamoto, and
J Sudo
December 1975,
The Journal of clinical endocrinology and metabolism,
J Terui, and
K Tamoto, and
J Sudo
June 1976,
Circulation research,
